Concerning advanced NSCLC, the most recent ASCO guidelines recommend each tumor to be tested for EGFR, ALK, ROS1, and BRAF aberrations in any adequate and well-preserved biopsy or cytology specimen, as molecular therapies exist for all aforementioned targets. The gene discussed is EGFR; the disease is neoplasm.